# Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma

> **NCT01634113** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 102 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** tiotropium-bromide
- **DRUG:** tiotropium-bromide
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01634113
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2015-06-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01634113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01634113, "Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01634113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*